🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Butterfly Learnings raises Rs 32 Cr in Series A round

EntrackrEntrackr · 1y ago
Butterfly Learnings raises Rs 32 Cr in Series A round
Medial

Butterfly Learnings, a platform in paediatric behavioural and developmental health, has raised Rs 32 crore in its Series A round ed by Insitor Impact Asia Fund II and Enzia Ventures, with participation from CIIE (IIMA Ventures), Foundation Botnar, 9 Unicorns, and Venture Catalysts. Earlier in 2022, the Mumbai-based startup had raised $2 million in its seed funding round from Insitor Partners, 9 Unicorns, Venture Catalysts, and others. The fresh proceeds will be used to fuel Butterfly Learnings’ expansion efforts as it plans to scale its tech enabled therapy programs. Founded by Sonam Kothari, Butterfly Learnings operate as a phygital platform that offers tailored support for children and families facing challenges related to neurodiversity. It employs over 250 in-house trained therapists, with operations extending to urban areas such as Pune, Nagpur, and Nasik. The platform’s core offerings include individualized therapy regimens based on applied behavior analysis (ABA), consultations with skilled pediatric neurologists or developmental pediatricians, and additional therapies such as occupational therapy, speech therapy, oral placement therapy, and sensory integration. Currently serving approximately 2,000 families across 30 centers in Maharashtra, the firm plans to extend its reach across multiple states and cities in India through a 200-center network.

Tvaster Genkalp raises $1.25 Mn in pre-Series A round

EntrackrEntrackr · 3m ago
Tvaster Genkalp raises $1.25 Mn in pre-Series A round
Medial

Title: Tvaster Genkalp raises $1.25 Mn in pre-Series A round Healthtech startup Tvaster Genkalp has raised $1.25 million in its pre-Series A round led by Ideaspring Capital. Existing backers such as Invigo Softwares and liver transplant expert Prof. Mohamed Rela also joined the round. The proceeds will be used to help expand and market Episcreen™ Liver, a new blood test that can detect liver cancer early with 90% accuracy. This test offers a better option than the current standard, Alpha-Fetoprotein (AFP), which has only 50% sensitivity. Founded in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, Tvaster is building high-accuracy, non-invasive tests for cancer. It aims to improve early detection and save lives, especially for liver cancer, which affects over 900,000 people globally every year. Tvaster has tested Episcreen™ Liver on over 600 patients and plans to partner with top diagnostic labs for wider access. The firm is also working on tests for bile duct cancer and childhood liver cancer treatment resistance. It recently won the ILTS Young Researcher Award and received a BIRAC BIG Grant for its work in cancer diagnostics.

MOC Cancer Care raises $18 Mn led by Elevation Capital

EntrackrEntrackr · 4m ago
MOC Cancer Care raises $18 Mn led by Elevation Capital
Medial

MOC Cancer Care raises $18 Mn led by Elevation Capital MOC Cancer Care & Research Centre, a network of community cancer centres, has raised $18 million in funding led by Elevation Capital. Previously, MOC raised $10 million from Tata Capital Healthcare Fund in January 2023 to expand its operations and technological capabilities. The proceeds will be used to expand operations, open new centres, and diversify the range of services offered, said the Mumbai-based company. It operates in the daycare oncology space, focusing primarily on chemotherapy and the medical management of cancer. Founded in 2018 by oncologists Dr Ashish Joshi, Dr Kshitij Joshi, Dr Pritam Kalaskar and Dr Vashishth Maniar, MOC is a concept turned enterprise and a chain of community cancer centres that work to simplify the journey for cancer patients by building an ecosystem that embodies crucial aspects like proximity and affordability. Over the past seven years, MOC claims to have treated over 4.5 lakh cancer patients with a highly qualified team of 47 oncologists while scaling operations to 24 centres in Mumbai, Pune, Rest of Maharashtra, Ahmedabad, Indore, and Chhattisgarh. In May 2024, the company expanded its services by joining hands with Hemato Oncology Clinic (HOC), which was the second-largest independent chain of community cancer care centres in India. This merger has allowed the company to expand its operations in the state of Gujarat. MOC will soon expand its operations in Delhi NCR and other parts of India and develop a molecular oncology lab. Recently, Vivek Mathur, Partner and Chief Operating Officer (COO) at Elevation Capital, left the venture capital firm after 14 years to focus on advisory and mentorship.

Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr

EntrackrEntrackr · 1y ago
Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr
Medial

Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The board at Immuneel Therapeutic has passed a special resolution to issue 1o equity shares and 8,164 Series A1 CCPS at an issue price of Rs 1,22,330 each to raise Rs 100 crore or $12 million, its regulatory filing accessed from the Registrar of Companies show. The company will use these investments for growth and expansion as decided by the board, the filings further added. As per TheKredible’s estimates, the firm has been valued at around Rs 587 crore or $71 million (post-allotment). Following the fresh proceeds, Taiba Middle East FZ holds a 17% stake in Immuneel Therapeutics. The round appears to be ongoing and it may raise more funds. The company has raised around $40 million to date including its $15 million Series A financing co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022. Founded by Biocon founder Kiran Mazumdar Shaw, oncologist and Pulitzer winner — Siddhartha Mukherjee and Kush Parwar, Immuneel Therapeutics is an Indian clinical-stage startup which is engaged in developing cell and gene therapies for cancer patients. It’s also working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer. The firm claims to offer therapies at one-third of the costs borne for gene therapies in America. While the company is yet to file its annual statements for FY24, six-year-old Immuneel Therapeutics remained at a pre-revenue stage in FY23. Its losses stood at Rs 39 crore in the fiscal year ending March 2023.

Lissun providing mental, emotional health solutions raises $1.3M led by IPV, Rainmatter, others

IndianStartupNewsIndianStartupNews · 1y ago
Lissun providing mental, emotional health solutions raises $1.3M led by IPV, Rainmatter, others
Medial

Gurgaon-based startup Lissun, specializing in mental and emotional health solutions, secured $1.3 million in seed funding, led by Inflection Point Ventures and Rainmatter Capital, a Zerodha subsidiary. Existing investors IvyCap Ventures, WFC, Growx Ventures, and angel investors also participated. Lissun will use the funds to enhance technology, expand services, and establish partnerships with healthcare institutions. Founded in 2021, Lissun offers tech-enabled mental health solutions, including therapy and guidance. They aim to address mental health challenges at scale, with over 15,000 paying customers and 30,000 therapy sessions conducted in 30 Indian cities.

OneCell Diagnostics raises $16 million in round led by Celesta Capital, others

Economic TimesEconomic Times · 7m ago
OneCell Diagnostics raises $16 million in round led by Celesta Capital, others
Medial

OneCell Diagnostics, a startup specializing in AI-powered cancer diagnostics, has raised $16 million in a series A funding round. The funding was led by Celesta Capital and included participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. OneCell plans to use the funds to expand to the US market with its liquid biopsy test, OncoIndx Alfa, which detects circulating tumor cells for precision diagnosis and treatment of cancer. The funding will also help the company democratize precision oncology by making cancer diagnostic testing more accessible and affordable. OneCell has already tested its technology in India and has partnerships with leading medical institutions.

Download the medial app to read full posts, comements and news.